Release issued 3rd December 2007

December 3, 2007, Waltham, Mass.  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the 2010 launch of Genentech/Roche/Chugai's Avastin for the treatment of Ovarian Cancer will drive the drug market to more than triple to  US1.6 billion by 2016.

The forthcoming Pharmacor report entitled Ovarian Cancer  finds that the launches in the United States and in Europe of Avastin in 2010 for first-line and maintenance treatment, Marshall Edwards' Phenoxodiol in 2011 for second-line treatment, and ViRexx's OvaRex in 2011 for maintenance therapy will drive growth of more than US$1.1 billion between 2006 to 2016. The report also finds that platinum-based regimens-the use of cell-damaging platinum compounds-will continue to be the cornerstone of treatment for ovarian cancer. Maintenance therapy with drugs that include Avastin and OvaRex will be given to an increasing portion of patients who demonstrate a complete response to first-line treatment.

"The mortality rate of ovarian cancer will continue to be high until the critical unmet needs of earlier diagnosis, prevention of relapse and treatment for platinum-resistant patients are met," said Mohamed Muhsin, analyst at Decision Resources. "A cost-effective screening program will remain elusive, but Avastin and Phenoxodiol will make impressive strides toward fulfilling some of the unmet needs in treatment."

About Ovarian Cancer
Ovarian Cancer is the leading cause of gynecologic cancer deaths in the Western world and the fifth most frequent cause of cancer death in women. The greatest unmet needs in the disease are long-term effective treatments for the following patient subpopulations: advanced-stage, chemotherapy-resistant and refractory patients. Although 80% of patients respond to primary therapy, the vast majority ultimately relapses and becomes resistant to chemotherapy.

About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

(25th January 2010) A Fibromyalgia drug that improves sleep quality more than Pfizer’s Lyrica would earn sizeable patient share in the U.S. and Europe

(19th January 2010) A larger proportion of Hepatitis C Non-Responder Patients will be treated with Telaprevir than Boceprevir

(18th January 2010) Celgene/Nippon Kayaku’s Calsed will become Decision Resources’ new clinical gold standard in 2013 for the treatment of Extensive-Disease Small-Cell Lung Cancer

(12th January 2010) Enbrel will remain Decision Resources’ clinical gold standard through 2018 for The Treatment of Rheumatoid Arthritis

(11th January 2010) For the treatment of Chronic Tophaceous Gout, a drug that resolves Tophi in less than one year would become the patient share leader in the U.S. and Europe